These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 1311472)
1. Anti-CMV hyperimmune globulin prophylaxis does not prevent CMV disease in CMV-negative renal transplant patients. Pakkala S; Salmela K; Lautenschlager I; Ahonen J; Häyry P Transplant Proc; 1992 Feb; 24(1):283-4. PubMed ID: 1311472 [No Abstract] [Full Text] [Related]
2. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis. Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909 [TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936 [TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies. Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495 [TBL] [Abstract][Full Text] [Related]
5. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection. Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125 [TBL] [Abstract][Full Text] [Related]
6. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease]. Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888 [TBL] [Abstract][Full Text] [Related]
7. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients. Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302 [TBL] [Abstract][Full Text] [Related]
10. Significant reduction of cytomegalovirus (CMV) disease by prophylaxis with CMV hyperimmune globulin plus oral acyclovir. Einsele H; Vallbracht A; Friese M; Schmidt H; Haen M; Dopfer R; Niethammer D; Waller HD; Ehninger G Bone Marrow Transplant; 1988 Nov; 3(6):607-17. PubMed ID: 2850830 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient. Uber L; Cofer J; Baliga P; Rajagopalan PR Transplant Proc; 1995 Oct; 27(5 Suppl 1):42-3. PubMed ID: 7482818 [No Abstract] [Full Text] [Related]
12. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients. Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406 [TBL] [Abstract][Full Text] [Related]
13. Prevention of CMV infection in transplant patients. Fishman JA Transpl Infect Dis; 1999; 1 Suppl 1():35-9. PubMed ID: 11565586 [TBL] [Abstract][Full Text] [Related]
14. [Cytomegalovirus hyperimmune globulin prophylaxis in bone marrow transplants in children with various diseases]. Ebell W; Blütters-Sawatzki R; Friedrich W; Hampl W; Kleihauer E Immun Infekt; 1985 Nov; 13(6):307-12. PubMed ID: 3000925 [TBL] [Abstract][Full Text] [Related]
15. Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients. Ozaki KS; Câmara NO; Galante NZ; Camargo LF; Pacheco-Silva A Int Immunopharmacol; 2005 Jan; 5(1):103-6. PubMed ID: 15589467 [TBL] [Abstract][Full Text] [Related]